Operation Trailblazer: Accelerating U.S. Clinical Trials to Counter China’s Rise

Recent data show China’s share of global clinical-trial starts surged from 1 % in 2009 to 32 % in 2023, and by 2024 China registered 39 % of all trials, overtaking the United States for the first time. The Cure Innovation Index survey cited at the BIO convention confirms the U.S. still leads in R&D innovation, but the speed, scale and cost advantages of Chinese sites threaten that edge.

Pharmaphorum

Operation Trailblazer (also called Operation TrialBlazer) bundles several FDA-led measures aimed at compressing the discovery-to-first-in-human (FIH) pipeline by six to twelve months. Key actions include:

What Operation TrialBlazer means for CDMOs and CMC strategy

• Expedited IND Pilot Program – a rolling IND submission platform that pairs sponsors with qualified research institutions (academic medical centers or CROs) to develop Phase 1 INDs and reduce clinical holds.

FDA - Food and Drug Administration

• Phase 1 IND Navigator & Contact Center – a consolidated web resource and a real-time help line (240-276-9358) to guide smaller companies through IND requirements and CMC expectations.

HHS and FDA propose clinical trial reforms to expedite drug development

• Updated CMC Guidance – clarifies phase-specific chemistry, manufacturing, and controls data, stating a fully validated commercial process is unnecessary at this stage, saving up to a year of preparation.

What Operation TrialBlazer means for CDMOs and CMC strategy

• Quantitative Systems Pharmacology (QSP) Draft Guidance – recommends using QSP modeling to determine the minimum anticipated biological effect level (MABEL) for dose selection, moving away from animal toxicology reliance.

HHS and FDA propose clinical trial reforms to expedite drug development

• Master-Protocol Draft Guidance – expands on basket, umbrella and platform trial designs to streamline multi-product studies.

HHS and FDA propose clinical trial reforms to expedite drug development

• Single-Trial Approval Guidance – outlines circumstances where one rigorous pivotal trial plus confirmatory evidence may satisfy the substantial-evidence standard.

HHS and FDA propose clinical trial reforms to expedite drug development

The FDA estimates the combined reforms could shave 6–12 months from early-stage timelines. Current averages show 380 days from a Pre-IND meeting request to IND submission, with a range up to 700 days. The agency projects Chinese-developed drugs could account for 35 % of FDA approvals by 2040 if trends continue.

What Operation TrialBlazer means for CDMOs and CMC strategy

HHS Secretary Robert F. Kennedy Jr. framed the effort as a reversal of “unnecessary barriers” that have driven research overseas, emphasizing America’s historic leadership in medical innovation. Acting FDA Commissioner Kyle Diamantas highlighted the urgency, noting the “growing share of phase 1 clinical trials moving overseas” threatens patient access and U.S. scientific standing. The FDA reiterated its commitment to maintain safety standards while eliminating redundant data requirements. NIH’s NCATS and ARPA-H’s ENGINE and UNICORN programmes were cited as complementary tools to accelerate rare-disease therapies and biomanufacturing.

HHS and FDA propose clinical trial reforms to expedite drug development

The Commissioner’s National Priority Voucher (CNPV) program, launched in June 2025 to fast-track priority drugs, faces criticism for limited transparency in candidate selection and perceived senior-leadership interference. Patient, industry and trade groups have called for a temporary pause. Additionally, stakeholders have expressed concern that moving to single-trial approvals may reduce evidentiary robustness, especially as the related draft guidance was delayed until mid-2025.

BioSpace

Sources differ on the public-comment deadline for the single-trial guidance (July 22 vs. August 24) and on China’s trial share (32 % vs. 39 %). No data are provided on how the new QSP approach will affect trial success rates, leaving a gap in outcome projections.

The Hill

• “America should be the best place in the world to develop new medicines, yet we have built a system that drives too much clinical research overseas,” — Robert F. Kennedy Jr., U.S. Secretary of Health

HHS and FDA propose clinical trial reforms to expedite drug development

• “We’ve been witness to a growing share of phase 1 clinical trials moving overseas, delaying opportunities for American patients and weakening the nation’s position as a global leader in biomedical research,” — Kyle Diamantas, Acting FDA Commissioner

The Hill

• “The CNPV program has also come under fire, however, for a perceived lack of transparency, particularly around candidate selection, as well as interference from the agency’s senior leaders.” — FDA spokesperson

BioSpace

• “ According to a Federal Register announcement, “QSP has emerged as a tool to model disease progression and complex drug–biological system interactions.” — FDA draft guidance

HHS and FDA propose clinical trial reforms to expedite drug development

• “a fully developed and validated commercial process is unnecessary at this stage.” — FDA, CMC guidance

What Operation TrialBlazer means for CDMOs and CMC strategy

The FDA will accept public comments on the Expedited IND pilot until 22 July and on the single-trial and QSP guidances by 24 August. Implementation of the rolling IND platform, expanded master-protocol framework, and CNPV revisions are slated for rollout in late 2025, with ongoing monitoring of timeline reductions and safety outcomes.

HHS and FDA propose clinical trial reforms to expedite drug development